Guardant Health is a leading precision oncology company focused on helping conquer cancerglobally through use of its proprietary tests, vast data sets and advanced analytics.
Theoncology platform leverages capabilities to drive commercial adoption, improve patient clinicaloutcomes and lower healthcare costs across all stages of the cancer care continuum.

Foundation Medicine’s highly validated portfolio of comprehensive genomic profiling testsprovides clinically-relevant genomic results for all advanced cancer patients regardless ofspecimen type. Find out more about the first FDA-approved test for solid tumors, our liquidbiopsy for solid tumors, and our test for hematologic malignancies at foundationmedicine.com/genomic-testing.

Will be added soon

Menarini Silicon Biosystems offers the new CELLSEARCH® Circulating Multiple Myeloma Cell (CMMC) Enumeration assay, the first-of-its-kind LDT, which directly measures levels of plasma cells in peripheral blood. The CELLSEARCH® CMMC enumeration test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, the test serially monitors plasma cell burden over time without requiring repeated bone marrow biopsies. Through our groundbreaking technology platforms and global lab services, we have standardized serial monitoring through cell-based liquid biopsy for a variety of conditions.

Will be added soon

Signatera is a personalized, tumor-informed ctDNA assay for molecular residual disease (MRD) detection and treatment response monitoring in patients previously diagnosed with cancer. Signatera is optimized to detect low levels of ctDNA, to help stratify high risk patients and optimize patient management. Discover more at: www.natera.com/oncology/signatera-advanced-cancer-detection/

Merck KGaA, Darmstadt, Germany is a science-led organization dedicated to making a meaningful difference in the lives of people affected by cancer. Our oncology research aims to leverage our synergistic portfolio to tackle challenging tumor types, as we work to illuminate a path to scientific breakthroughs to transform patient outcomes. Learn more at www.merckgrouponcology.com

Bio-Rad is a global leader for life science research and clinical diagnostics that advance several applications for liquid biopsy. For assessing cfDNA and ctDNA in liquid biopsies, Droplet Digital PCR (ddPCR) offers unrivaled detection, precision, and absolute quantification. Celselect
Slide™ Technology with the Genesis System enables CTC enrichment and enumeration applications.

Sermonix Pharmaceuticals Inc is a privately held biopharmaceutical company with a precision medicine focus for bringing targeted oncology products through development, approval, and commercialization. Sermonix’s Lasofoxifene, entering phase 3, is thought to be a potent
third-generation selective estrogen receptor modulator (SERM) with high affinity for the estrogen receptor 1 (ESR1).

C2i Genomics deploys an innovative ctDNA MRD solution for personalized cancer detection and monitoring. C2i’s whole-genome technology provides ultra-high sensitivity with significantly reduced lab operation complexity, eliminate the need to develop a patient-specific assay, and allowing earlier detection of recurrent cancer, to inform better treatment decisions and improve outcomes.